AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer 

Researchers promises that AMG 509 provides a targeted immunotherapy approach to engage a patient’s T cells to kill STEAP1-expressing tumor cells and represents a new treatment option for mCRPC and potentially more broadly for prostate cancer. Immunotherapy in prostate cancer has met with limited success due to the immunosuppressive microenvironment and lack of tumor-specific targets.

Posted on:

Subscribe to our Newsletter

Full Name



Your form submitted successfully!


Sorry! your form was not submitted properly, Please check the errors above.